Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25911294
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Paediatr+Drugs
2015 ; 17
(4
): 273-81
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Central Precocious Puberty: Update on Diagnosis and Treatment
#MMPMID25911294
Chen M
; Eugster EA
Paediatr Drugs
2015[Aug]; 17
(4
): 273-81
PMID25911294
show ga
Central precocious puberty (CPP) is characterized by the same biochemical and
physical features as normally timed puberty but occurs at an abnormally early
age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In
contrast, ~50% of boys with CPP have an identifiable cause. The diagnosis of CPP
relies on clinical, biochemical, and radiographic features. Untreated, CPP has
the potential to result in early epiphyseal fusion and a significant compromise
in adult height. Thus, the main goal of therapy is preservation of height
potential. The gold-standard treatment for CPP is gonadotropin-releasing hormone
(GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems
and durations of action are commercially available. While the outcomes of
patients treated for CPP have generally been favorable, more research about the
psychological aspects, optimal monitoring, and long-term effects of all forms of
GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa
exist and await additional investigation.
free
free
free
